ZVRA Stock Analysis: Buy, Sell, or Hold?
ZVRA - Zevra Therapeutics, Inc. Common Stock
$13.08
0.08 (0.62%)
▲
5d:
+3.4%
30d:
+30.41%
90d:
+42.95%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When ZVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZVRA shows positive signals but monitor for confirmation. Market pricing in 2.4% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: ZVRA shows positive signals but monitor for confirmation. Market pricing in 2.4% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.70
Based on 0.9% avg growth
INTRINSIC VALUE TODAY
$7.89
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZVRA is currently trading at $13.08, which is considered extended relative to its 30-day fair value range of $10.60 to $12.87. The stock's valuation (Forward PE: 10.9) is in line with its historical norms (10.2). At these levels, the market is pricing in 2.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ZVRA is in a strong uptrend. Immediate support is located at $12.18, while resistance sits at $14.27.
Market Sentiment: ZVRA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $27.89 (+113.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZVRA is in a strong uptrend. Immediate support is located at $12.18, while resistance sits at $14.27.
Market Sentiment: ZVRA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $27.89 (+113.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.60 -
$12.87
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 113.2% below Wall St target ($27.89)
- NEUTRAL: Market pricing in 2.4% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$10.60 -
$12.87
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.05
(8.1%)
Support & Resistance Levels
Support Level
$12.18
Resistance Level
$14.27
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.95
Wall Street Target
$27.89
(+113.2%)
Revenue Growth (YoY)
77.5%
Profit Margin
101.6%
Valuation Premium vs History
+2.4% premium
PE vs Historical
11.0 vs 10.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.4%
(market-implied from PE analysis)
1-Year Target
$13.39
(+2%)
2-Year Target
$13.72
(+5%)
3-Year Target
$14.04
(+7%)
3-Yr Target (if PE normalizes)
(PE: 11→10)
PE COMPRESSION
$13.09
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: -2.3%)
$24.26
(+86%)
Base:
(SPY PE: 10.9, Growth: -2.3%)
$12.19
(-7%)
Bear:
(PE: 9.3, Growth: -2.3%)
$10.36
(-21%)
📈
Valuation based on Current Earnings
Trailing PE: 6.29 | Current EPS (TTM): $2.01
Bull Case
$8.27
(-36%)
Analyst growth -40.5%, PE expands to 6.9
Base Case
$7.52
(-42%)
Market implied -40.5%, PE stable at 6.3
Bear Case
$8.60
(-34%)
Severe decline -20.0%, PE contracts to 5.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 5:23 PM ET
Data refreshes hourly during market hours. Next update: 6:23 PM
Data refreshes hourly during market hours. Next update: 6:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Joshua Schafer
SELL
10500 shares
2026-02-03
Timothy J Sangiovanni
SELL
3000 shares
2026-02-03
Neil F Mcfarlane
SELL
91000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 60 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 69 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
Advanced ZVRA Option Strategies
Professional options setups generated by AI based on today's ZVRA price and gamma walls.
